Drug intelligence / Profile preview

Cetaphil

Development stage
Unknown
Lead developer
Galderma
Modality
Small Molecules
Administration
Topical
01

Overview

Cetaphil is a prominent brand of dermatological skincare products specifically engineered for individuals with sensitive, dry, or compromised skin, including those suffering from conditions like atopic dermatitis and psoriasis. Originally developed in 1947 and currently owned by Galderma, the Cetaphil portfolio encompasses a wide range of cleansers, moisturizers, and sunscreens. The therapeutic efficacy of Cetaphil products, particularly the moisturizers, is derived from a combination of humectants such as glycerin, which attract water into the stratum corneum, and occlusives like petrolatum and dimethicone, which form a physical barrier to prevent transepidermal water loss (TEWL). Many formulations also incorporate skin-soothing agents like panthenol and niacinamide to support skin barrier repair and reduce inflammation. While primarily available over-the-counter, Cetaphil is frequently integrated into clinical treatment regimens as an essential adjunctive therapy to maintain skin integrity and enhance the efficacy of topical pharmacological treatments.

Brand names
Cetaphil

Beyond the preview

Go deeper on Cetaphil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cetaphil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call